source
- Health tech investors shift focus to larger funding rounds, Cityblock secures $116 millionThroughout the past year, investors in digital health have increasingly favored megafunding rounds rather than smaller seed or Series A deals. In August, community-health startup Cityblock announc…
- Ultragenyx gene therapy for Angelman syndrome fails Phase 3 trial, company to cut expensesAn experimental gene therapy targeting Angelman syndrome did not meet its primary endpoint in a Phase 3 study, according to Ultragenyx. The trial showed no difference between the therapy, GTX-102,…